These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 24854894)

  • 1. Measurement of subvisible particulates in lyophilised Erwinia chrysanthemi L-asparaginase and relationship with clinical experience.
    Gervais D; Corn T; Downer A; Smith S; Jennings A
    AAPS J; 2014 Jul; 16(4):784-90. PubMed ID: 24854894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved pharmacokinetic and pharmacodynamic profile of a novel PEGylated native Erwinia chrysanthemi L-Asparaginase.
    Modi T; Gervais D
    Invest New Drugs; 2022 Feb; 40(1):21-29. PubMed ID: 34468906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can recombinant technology address asparaginase Erwinia chrysanthemi shortages?
    Maese L; Rizzari C; Coleman R; Power A; van der Sluis I; Rau RE
    Pediatr Blood Cancer; 2021 Oct; 68(10):e29169. PubMed ID: 34105243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of glycation levels in Erwinia chrysanthemi asparaginase drug product by liquid chromatography - mass spectrometry.
    Kanda P; Minshull TC
    Eur J Pharm Sci; 2020 Mar; 145():105253. PubMed ID: 32027934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Back to the future: the amazing journey of the therapeutic anti-leukemia enzyme asparaginase
    Tong WH; Rizzari C
    Haematologica; 2023 Oct; 108(10):2606-2615. PubMed ID: 37470157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acidic isoforms of Erwinase form part of the product: Correlation with clinical experience.
    Gervais D
    Biologicals; 2020 Mar; 64():28-33. PubMed ID: 31959505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant deamidated mutants of Erwinia chrysanthemi L-asparaginase have similar or increased activity compared to wild-type enzyme.
    Gervais D; Foote N
    Mol Biotechnol; 2014 Oct; 56(10):865-77. PubMed ID: 24870616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cross-reactivity of anti-asparaginase antibodies against different L-asparaginase preparations.
    Zalewska-Szewczyk B; Gach A; Wyka K; Bodalski J; Młynarski W
    Clin Exp Med; 2009 Jun; 9(2):113-6. PubMed ID: 19184328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial.
    Plourde PV; Jeha S; Hijiya N; Keller FG; Silverman LB; Rheingold SR; Dreyer ZE; Dahl GV; Mercedes T; Lai C; Corn T
    Pediatr Blood Cancer; 2014 Jul; 61(7):1232-8. PubMed ID: 24436152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreasing the immunogenicity of Erwinia chrysanthemi asparaginase via protein engineering: computational approach.
    Yari M; Eslami M; Ghoshoon MB; Nezafat N; Ghasemi Y
    Mol Biol Rep; 2019 Oct; 46(5):4751-4761. PubMed ID: 31290058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and Characterization of Erwinia Chrysanthemi l-Asparaginase Variants with Diminished l-Glutaminase Activity.
    Nguyen HA; Su Y; Lavie A
    J Biol Chem; 2016 Aug; 291(34):17664-76. PubMed ID: 27354283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase.
    Chien WW; Allas S; Rachinel N; Sahakian P; Julien M; Le Beux C; Lacroix CE; Abribat T; Salles G
    Invest New Drugs; 2014 Oct; 32(5):795-805. PubMed ID: 24829072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural Characterisation of Non-Deamidated Acidic Variants of Erwinia chrysanthemi L-asparaginase Using Small-Angle X-ray Scattering and Ion-Mobility Mass Spectrometry.
    Gervais D; King D; Kanda P; Foote N; Elliott L; Brown P; Lee NO; Thalassinos K; Pizzey C; Rambo R; Minshull TC; Dickman MJ; Smith S
    Pharm Res; 2015 Nov; 32(11):3636-48. PubMed ID: 26040662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In silico identification and characterization of antineoplastic asparaginase enzyme from endophytic bacteria.
    Zadeh Hosseingholi E; Neghabi N; Molavi G; Gheibi Hayat SM; Shahriarpour H
    IUBMB Life; 2020 May; 72(5):991-1000. PubMed ID: 31981306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteins from Erwinia asparaginase Erwinase ® and E. coli asparaginase 2 MEDAC ® for treatment of human leukemia, show a multitude of modifications for which the consequences are completely unclear.
    Bae N; Pollak A; Lubec G
    Electrophoresis; 2011 Jul; 32(14):1824-8. PubMed ID: 21769889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Asparaginase Erwinia chrysanthemi (Erwinaze®): a guide to its use in acute lymphoblastic leukemia in the USA.
    Keating GM
    BioDrugs; 2013 Aug; 27(4):413-8. PubMed ID: 23794007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.
    Salzer WL; Asselin BL; Plourde PV; Corn T; Hunger SP
    Ann N Y Acad Sci; 2014 Nov; 1329():81-92. PubMed ID: 25098829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comprehensive review on microbial l-asparaginase: Bioprocessing, characterization, and industrial applications.
    Chand S; Mahajan RV; Prasad JP; Sahoo DK; Mihooliya KN; Dhar MS; Sharma G
    Biotechnol Appl Biochem; 2020 Jul; 67(4):619-647. PubMed ID: 31954377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subvisible Particle Analysis of 17 Monoclonal Antibodies Approved in China Using Flow Imaging and Light Obscuration.
    Guo S; Yu C; Guo X; Jia Z; Yu X; Yang Y; Guo L; Wang L
    J Pharm Sci; 2022 Apr; 111(4):1164-1171. PubMed ID: 34551350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asparaginase Erwinia chrysanthemi effectively depletes plasma glutamine in adult patients with relapsed/refractory acute myeloid leukemia.
    Emadi A; Law JY; Strovel ET; Lapidus RG; Jeng LJB; Lee M; Blitzer MG; Carter-Cooper BA; Sewell D; Van Der Merwe I; Philip S; Imran M; Yu SL; Li H; Amrein PC; Duong VH; Sausville EA; Baer MR; Fathi AT; Singh Z; Bentzen SM
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):217-222. PubMed ID: 29119293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.